Clinical trials: Refractory Colorectal Cancer
Colorectal Cancer
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
- Trial name
- RECOURSE (NCT01607957)
- Testing
- TAS-102
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 800 people
- Sponsor
- Taiho Oncology, Inc.
Metastatic Colorectal Cancer
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer
This study aims to evaluate the safety and efficacy of Immuncell-LC, the adoptive immuntherapeutic agent composed of a CIK cell agent, to treat patients with metastatic colorectal cancer, which are refractory to the 3rd-line…
- Trial name
- NCT03220984
- Testing
- Immuncell-LC intravenous infusion using a CIK cell agent
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Gangnam Severance Hospital
Colorectal Carcinoma
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and…
- Trial name
- NCT00051987
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Where
- 22 sites in United States
- Volunteers
- 175 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Metastatic Colorectal Cancer
Sacituzumab Govitecan in Metastatic Colorectal Cancer
This is a Phase: II/III, open-label, multicenter (at least four centers in Germany) study of Sacituzumab Govitecan (SG) in metastatic colorectal cancer patients who are refractory to at least two lines of standard of care…
- Trial name
- TROPHIT1 (NCT06243393)
- Testing
- Sacituzumab Govitecan (SG), Physicians Choice (PhC).
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Heidelberg
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Colorectal Neoplasms, Neuroendocrine Tumors
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
This is a prospective pilot study designed to document safety and efficacy of liver-directed therapy for colorectal, neuroendocrine, cholangiocarcinoma, melanoma, and breast cancer metastases to the liver using Yttrium-90 glass…
- Conditions
- Colorectal Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Melanoma
- Trial name
- NCT01290536
- Testing
- Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)
- Volunteers
- 42 people
- Sponsor
- Nicholas Fidelman, MD
Colorectal Cancer
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
This study will determine if nimotuzumab provides a benefit in this type of cancer when given in combination with irinotecan. The study will test: How long any good effects last. How bad any side effects are.
- Trial name
- NCT00493857
- Testing
- Nimotuzumab Humanized Monoclonal Antibody, Nimotuzumab
- Where
- 12 sites in Canada
- Volunteers
- 100 people
- Sponsor
- YM BioSciences
Liver Cancer, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Liver Cancer, Pancreatic Cancer, Brain Tumor, Breast Cancer
- Trial name
- NCT02541370
- Testing
- anti-CD133-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Colorectal Cancer, Colon Cancer
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) and Aldesleukin (interleukin-2, IL-2) immunotherapy in patients with…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectum Cancer
- Trial name
- BAH248 (NCT06530303)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Liver Metastasis Colon Cancer
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
Observational, feasibility study investigating biological aspects in patients with liver metastasis from colorectal cancer undergoing treatment with SIRT, by translational analysis of biological samples.
- Trial name
- SIRT (NCT04491929)
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Aarhus University Hospital
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Metastatic Colorectal Cancer
Metformin and 5-fluorouracil for Refractory Colorectal Cancer.
This is a phase II trial to evaluate efficacy and safety of Metformin and Fluorouracil in patients with metastatic colorectal cancer (CRC) who have progressed after Oxaliplatin and Irinotecan based chemotherapy.
- Trial name
- NCT01941953
- Testing
- Metformin and Fluorouracil
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colorectal Cancer, Pancreatic Cancer
BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
This study is an exploratory research on single arm, open, and improved "3+3" dose escalation. BGT007 will explore two dose groups, namely (Group A: 3.0X10 ^ 8 3 cases, Group B: 6.0X10 ^ 8 3 cases), and receive the same dose…
- Trial name
- NCT06645301
- Testing
- Group A, Group B
- Volunteers
- 15 people
- Sponsor
- BioSyngen Pte Ltd
Metastatic Colorectal Cancer
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
This is a Phase Ib study to evaluate the safety and preliminary anti-tumor activity of pembrolizumab in combination with pemetrexed with or without oxaliplatin in patients with chemo-refractory microsatellite stable (MSS)…
- Trial name
- NCT03626922
- Testing
- Pembrolizumab, Pemetrexed, Oxaliplatin
- Where
- 15 sites in United States
- Volunteers
- 33 people
- Sponsor
- NSABP Foundation Inc
Colorectal Adenocarcinoma, Colon Cancer
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Data from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizing cabozantinib combined with…
- Conditions
- Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer
- Trial name
- NCT04963283
- Testing
- Cabozantinib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Colorado, Denver
Neuroendocrine Tumors, Colorectal Cancer
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen…
- Conditions
- Neuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT06055439
- Testing
- CHM-2101 CAR-T cells
- Where
- 4 sites in United States
- Volunteers
- 135 people
- Sponsor
- Chimeric Therapeutics